CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages.
about
Human T cell aging and the impact of persistent viral infectionsCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsInfection in Organ Transplantation.The role of macrophage polarization in infectious and inflammatory diseasesThe pros and the cons of mTOR inhibitors in kidney transplantation.Release of human cytomegalovirus from latency by a KAP1/TRIM28 phosphorylation switchTuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.Human cytomegalovirus interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to repress host immune responsesActivation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.Proliferation signal inhibitor toxicities after thoracic transplantation.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Potential of protein kinase inhibitors for treating herpesvirus-associated disease.Immune responses of macrophages and dendritic cells regulated by mTOR signalling.Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?MicroRNAs in kidney transplantation.Safety of mTOR inhibitors in adult solid organ transplantation.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.Torque Teno Virus Load-Inverse Association With Antibody-Mediated Rejection After Kidney Transplantation.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro.Human cytomegalovirus infection of M1 and M2 macrophages triggers inflammation and autologous T-cell proliferation.Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection.Human Macrophages Escape Inhibition of Major Histocompatibility Complex-Dependent Antigen Presentation by Cytomegalovirus and Drive Proliferation and Activation of Memory CD4+ and CD8+ T Cells.Role of Human Macrophage Polarization in Inflammation during Infectious Diseases.
P2860
Q21131206-6E9701BA-D252-496E-A6E6-31673F7B6F16Q27023452-5D360B04-42B5-4603-9BA2-C178646FE389Q30238810-2E1E5E61-B3B4-4B14-9D61-BBB3D14D0BB0Q30413135-2F665B6A-3FF1-4580-8C9B-177538420FD1Q33412367-957A8BE3-AF39-4231-82DD-32D1EA616BD1Q35260579-965E9B16-D1E4-4AB4-AF72-D74FCBAE3DE3Q35861166-6C64819D-1585-40E6-846C-FFC2D1B6CEA2Q37123220-B03FD4E8-005C-4492-8611-CB6828A2C118Q37649641-69AF9EFA-F46F-4F1D-A362-C6DA423BBA02Q37649687-E71A1B21-9343-49A6-B4BE-B133FA3B8DFEQ38044748-050FBE86-4CC6-426C-8D5F-7B56C33812EDQ38061056-356D4C0A-C934-4270-A856-BEA264A24489Q38100859-940D65A1-BD5F-4B64-A3E2-9F6A0218BCB6Q38122223-050EFCDB-EC5A-48AE-BA15-5F5B65C2FD26Q38190678-617B7759-8A84-4794-9912-B5772D8D8724Q38244516-DDE4EDF4-18EF-4F30-8DF6-651F44B17C9EQ38669190-90811C62-DA05-4DFE-94CB-4D2E46829995Q38711763-F934834D-3A3D-4D73-980F-65D6DA9FC9EBQ38779846-F1328D6F-8FF6-4AA6-AA0D-F976D8264DCEQ38805253-F6751C59-9446-4411-9BD4-FA8CDB686AA5Q38831291-6FE2397F-5F93-47D6-8DD7-4589680BCA6CQ38875887-0BEE1C35-67BC-49A6-B18B-24E0A68C8035Q38947867-BC1A0797-41E0-4D13-897D-FA378C1990F2Q38962103-185EACAB-E9DA-4C9D-834C-CBDAA209CB77Q40856064-52C5C7E6-0683-45BF-8FE1-56FB9C923939Q42208780-1F70A874-DEC8-4BAC-B7F8-7E435FF79832Q42531590-FCB93537-0E2E-4DB2-BB2C-07F868E05D96Q43523397-557BB602-0096-4D23-B3C0-DFA9273443F4Q52691329-F8FCB10A-30DB-4E39-A76A-70B96813E07EQ55401180-934EED6B-B7F3-4DCB-876B-7E41A84FBC5FQ55716397-9E56FFD8-F9CA-4E74-B7FA-8B66EFFFC68B
P2860
CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
CMV late phase-induced mTOR ac ...... n polarized human macrophages.
@en
CMV late phase-induced mTOR ac ...... n polarized human macrophages.
@nl
type
label
CMV late phase-induced mTOR ac ...... n polarized human macrophages.
@en
CMV late phase-induced mTOR ac ...... n polarized human macrophages.
@nl
prefLabel
CMV late phase-induced mTOR ac ...... n polarized human macrophages.
@en
CMV late phase-induced mTOR ac ...... n polarized human macrophages.
@nl
P2093
P2860
P50
P1476
CMV late phase-induced mTOR ac ...... in polarized human macrophages
@en
P2093
E Puchhammer
G J Zlabinger
K Katholnig
M Antlanger
M D Säemann
M Poglitsch
P2860
P304
P356
10.1111/J.1600-6143.2012.04002.X
P407
P577
2012-03-05T00:00:00Z